Atopic Dermatitis

SAN DIEGO — In this Healio video perspective from the American Academy of Dermatology Annual Meeting, Alphyn Biologics CEO Neal Koller discusses new data from the company’s phase 2a trial of AB-101a for the treatment of atopic dermatitis.

In this Healio exclusive video, Steven R. Feldman, MD, PhD, discussed hidradenitis suppurativa research from the American Academy of Dermatology Annual Meeting, examining two studies into its treatment.

SAN DIEGO — Researchers found that children with moderate to severe atopic dermatitis have a higher mean weight and BMI, but a lower mean height, than healthy children, according to a poster presented here.

SAN DIEGO — Ruxolitinib cream improved quality of life outcomes, including sleep and itch, in children aged 2 to 11 years with atopic dermatitis, according to a poster presented at the American Academy of Dermatology Annual Meeting.

Babies born during the lockdown of March through May 2020 developed significant differences in their microbiome and less atopic dermatitis compared with babies born prior to this period, according to a study published in Allergy.

SAN DIEGO — Children with vs. without atopic dermatitis are more likely to experience learning and memory difficulties, according to a poster presented at the American Academy of Dermatology Annual Meeting.

SAN DIEGO — Atopic dermatitis improvement was found with lebrikizumab treatment in patients with skin of color, according to interim study results presented at the American Academy of Dermatology Annual Meeting.

WASHINGTON — Infants who were exposed to acid-suppressive medications had increased risk for developing food allergy, according to an abstract presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

SAN DIEGO — Patients with nonsegmental vitiligo continually improved with upadacitinib treatment up to 1 year, according to a speaker at the American Academy of Dermatology Annual Meeting.

SAN DIEGO — At the American Academy of Dermatology Annual Meeting, Galderma announced new data demonstrating nemolizumab’s long-term efficacy in treating prurigo nodularis and atopic dermatitis, according to a press release.